Compare LPTH & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | VOR |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.1M | 755.7M |
| IPO Year | 2011 | 2021 |
| Metric | LPTH | VOR |
|---|---|---|
| Price | $14.29 | $15.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $13.33 | ★ $45.44 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $83.04 | N/A |
| Revenue Next Year | $24.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $1.85 | $0.13 |
| 52 Week High | $15.24 | $49.95 |
| Indicator | LPTH | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.61 | 54.63 |
| Support Level | $9.60 | $11.38 |
| Resistance Level | $15.24 | $16.88 |
| Average True Range (ATR) | 1.14 | 1.62 |
| MACD | 0.35 | 0.07 |
| Stochastic Oscillator | 92.29 | 52.41 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.